MeOP — Chromatography Helps Identify the Latest Legal High
Oct 24 2015
There were 101 new psychoactive substances (NPS) recognised in 2014 according to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) — showing a steady increase year-on-year of new psychoactive compounds. Another name for the psychoactive substances is legal highs on the basis that they have not come under the scrutiny of a country’s law-makers — but that is not always true.
Searching for the next high
People sell and use legal highs to try and get around existing drug laws — with it being easier and quicker to release a new legal high than it is for the authorities to control or legislate against them. The NPS now being sold to the public are designed to imitate an existing psychoactive drug that is already controlled — giving the same effects because it is structurally similar with slightly different functional groups.
In 2013 the compound methoxypiperamide (MeOP) was reported to the EMCDDA as a NPS after being found for sale online. MeOP and its synthesis were first described in 1968 when it was developed as a potential drug for hypertension, but its effects and how it breaks down in the body are unknown.
Its interest as a legal high is because of its similarity to benzylpiperazide (BZP), a member of the piperazide class of stimulants that mimic the effects of ecstasy. BZP has been shown to affect the noradrenaline, serotonin and dopamine pathways. Following an EMCDDA assessment, controls were introduced on BZP in 2008 and it is now illegal to sell BZP in several countries including the UK — hence the interest in mimics.
Knowing how drugs breakdown in the body is part of the process of understanding a drug and its effects — but it also enables health experts to give the correct treatment where necessary. It is known that the metabolites of piperazides can be metabolites of medicines, so metabolite identification can be difficult.
A recent study has concentrated on identifying some of the metabolites of MeOP in rat’s urine and to see how these metabolites react with human enzymes. Reporting in the Journal of Mass Spectrometry, Meyer et al used gas and liquid chromatography to separate the metabolites before they were identified using mass spectrometry. The use of chromatography and mass spectrometry to identify metabolites is discussed in the article, Advances in Multi-mode Mass Spectrometry for Tissue Imaging Studies.
The team found that MeOP and many metabolites were excreted in the rat’s urine — and that they could be detected and identified using GC-MS and LC/MS urine tests. This means that there could be a method to identify whether MeOP has been taken — although it was noted that tests should be carried out to make sure the same metabolites seen here are the best means to confirm human consumption.
Do you know what you are taking?
Image By Ksd5 (Own work) [CC0], via Wikimedia Commons
In This Edition Modern & Practical Applications - Analysis of Cannabidiol in CBD products by SFC-CD-MS - Faster results with SFC for the analysis of choline and acetylcholine in rat cerebros...
View all digital editions
Sep 21 2021 Lagos, Nigeria
Sep 29 2021 Essen, Germany
Oct 03 2021 Prague, Czech Republic
Oct 05 2021 Paris, France
Oct 10 2021 Palm Springs, CA, USA & Virtual